While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Exclusive: OpenEvidence aims to be ‘Disney+’ with new JAMA deal. OpenEvidence this morning announced it has a new multi-year ...

And it’s never a bad time to re-read some of the team’s excellent, award-winning coverage on the company: Last week, key ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The NIH archives of the Human Genome Project could fall victim to Trump administration cuts, writes a former archivist.

WASHINGTON — House Republicans’ tax bill would lead to nearly 11 million people losing health insurance, providing a key ...

U.S. research on HIV, tuberculosis, Covid-19, mpox, and other fast-moving epidemics is under threat by a hastily announced ...

An internal document reveals how UnitedHealth Group's leadership prepared to downplay complaints about its business practices ...

In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused notable weight loss in mice ...

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help, STAT's Adam Feuerstein writes.

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...